Pharmaceutical companies Eli Lilly and Novo Nordisk are in a century-long rivalry for dominance in the $80 billion weight-loss drug market. Eli Lilly's new drug, Zepbound, aims to help patients cut over 20% of their body weight and potentially turn Eli Lilly into the first trillion-dollar drug company. The podcast explores the contrasting strategies of the two companies in weight-loss drug development, the impact of innovation, and the ongoing competition in the market, including the potential entry of other drug makers.
Read more
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
Eli Lilly's new weight loss drug, Zepbound, which combines GLP1 and GIP gut hormones, has shown significant weight loss results up to 21%, generating interest among investors and potentially positioning Eli Lilly as the first-ever trillion-dollar drug company.
The century-long rivalry between Eli Lilly and Novo Nordisk in the treatment of diabetes extends to the weight loss drug market, with Novo Nordisk leading initially but Eli Lilly entering the market with Zepbound and intensifying the competition as more drug makers enter the market.
Deep dives
The rise of weight loss drugs: Ozempic and Zepbound
Ozempic, a weight loss drug, gained popularity in recent years, leading the interest in weight loss drugs. Novo Nordisk was the front runner with Ozempic, while Eli Lilly focused on Alzheimer's research. However, with the new drug Zepbound, Eli Lilly entered the weight loss market. Zepbound works differently from its competitors by combining GLP1 and another gut hormone called GIP. It has shown significant weight loss results, reaching up to 21%. This new drug has generated interest among investors, making some predict that Eli Lilly could become the first-ever trillion-dollar drug company.
The rivalry between Eli Lilly and Novo Nordisk in the weight loss drug market
Eli Lilly and Novo Nordisk have been competitors in the treatment of diabetes for the past 100 years. Eli Lilly initially dismissed the potential of GLP1 drugs for obesity, while Novo Nordisk pursued research in this area. Novo Nordisk's drug, Sexenda, became the first FDA-approved GLP1 drug for weight loss. Later, they developed Ozempic, which showed substantial weight loss results. Eli Lilly, facing setbacks in Alzheimer's research, shifted its focus to weight loss drugs and developed Zepbound. The competition between these two companies continues as more drug makers enter the market.
The future of weight loss drugs and the impact on Eli Lilly's growth
The success of weight loss drugs like Zepbound and Ozempic depends on their effectiveness and market acceptance. Zepbound, with its unique combination of gut hormones, is believed to have an advantage over its competitors. Analysts predict Eli Lilly's stock value could soar, potentially making it the first trillion-dollar drug company. However, factors such as side effects and high costs may deter some potential users. Other drug makers are also developing weight loss drugs, introducing more competition. The future of the weight loss drug market remains uncertain, and the next breakthrough drug is yet to be determined.
The multi-billion dollar weight-loss drug market has ballooned in the past few years. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry.
Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts think it will turn Eli Lilly into the first ever trillion-dollar drug company.
(Corrects characterization of the current size of the weight-loss drug market)